Binney Street Capital is Dana-Farber’s first-ever venture fund that will capitalize on investment opportunities in startup companies that were created either with Dana-Farber intellectual property or were co-founded by a Dana-Farber investigator.

• Identify and develop business and partnering opportunities between Dana-Farber investigators and biopharma / investors• Manage Dana-Farber’s innovative venture-philanthropy collaboration with MPM Capital• Oversee Dana-Farber’s Pipeline Accelerator Program which financially supports the advancement of high-impact science to de-risk, increase the value, and accelerate commercialization of Dana-Farber technologies.

NextRNA is transforming the non-coding RNA therapeutic space and is shifting the concept of undruggable into druggable. NextRNA is based on unique platform that I helped co-develop in the Novina lab.

Microbial Machines is developing synthetically engineered bacteria to specifically detect and treat diseases of the alimentary track.

Laboratory of Dr. Carl Novina with co-mentorship by Entrepreneur-in-Residence, Fred Mermelstein PhD• Shaped the scientific direction of lab research and led efforts relating to the commercialization of platform technologies• Managed the development and execution of research programs and supported their growth through conception of and writing federal, foundation, and commercial award applications • Led diligence and commercialization efforts on platform technologies to strengthen IP position and secure a major biopharmaceutical partnership

QuantumCyte pioneered QCPRECISE, an automated tissue dissection and AI integrated platform to modernize pathology and improve patient outcomes

Laboratory of Dr. Adam Schrum and Dr. Claudia NeuhauserI developed a highly-sensitive, multiplexed, microsphere-based platform to measure protein-protein interactions. I identified dysregulated signaling pathways and novel signatures in autoimmune patient T cells (Science Signaling, 2016) and mechanistically demonstrated that quantitative proximal signaling (and not qualitative different signals) specify thymic selection outcomes (Science Immunology, 2019).